prikaz prve stranice dokumenta Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis
  Download
PDF 1.07 MB
Scientific paper - Original scientific paper
Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis
Annals of Hematology, 99 (2020), 12; 2779-2785. https://doi.org/10.1007/s00277-020-04239-4
Lucijanić, Marko; Galušić, Davor; Krečak, Ivan; Sedinić, Martina; Holik, Hrvoje; Periša, Vlatka; Morić Perić, Martina; Zekanović, Ivan; Štoos-Veić, Tajana; Kušec, Rajko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Lucijanić, M., Galušić, D., Krečak, I., Sedinić, M., Holik, H., Periša, V. ... Kušec, R. (2020). Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis. Annals of Hematology, 99. (12), 2779-2785. doi: 10.1007/s00277-020-04239-4

Lucijanić, Marko, et al. "Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis." Annals of Hematology, vol. 99, no. 12, 2020, pp. 2779-2785. https://doi.org/10.1007/s00277-020-04239-4

Lucijanić, Marko, Davor Galušić, Ivan Krečak, Martina Sedinić, Hrvoje Holik, Vlatka Periša, Martina Morić Perić, Ivan Zekanović, Tajana Štoos Veić and Rajko Kušec. "Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis." Annals of Hematology 99, no. 12 (2020): 2779-2785. https://doi.org/10.1007/s00277-020-04239-4

Lucijanić, M., et al. (2020) 'Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis', Annals of Hematology, 99(12), pp. 2779-2785. doi: 10.1007/s00277-020-04239-4

Lucijanić M, Galušić D, Krečak I, Sedinić M, Holik H, Periša V, and sur.. Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis. Annals of Hematology [Internet]. 2020 December [cited 2024 November 26];99(12):2779-2785. doi: 10.1007/s00277-020-04239-4

M. Lucijanić, et al., "Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis", Annals of Hematology, vol. 99, no. 12, pp. 2779-2785, December 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:588865. [Accessed: 26 November 2024]

Metadata
Title (english)Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis
AuthorMarko Lucijanić
AuthorDavor Galušić
AuthorIvan Krečak
AuthorMartina Sedinić
AuthorHrvoje Holik
AuthorVlatka Periša
AuthorMartina Morić Perić
AuthorIvan Zekanović
AuthorTajana Štoos-Veić
AuthorRajko Kušec
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
We retrospectively investigated a cohort of 176 myelofibrosis patients (128 primary-PMF; 48 secondary-SMF) from five hematology centers. The presence of chronic kidney disease (CKD) was determined in addition to other clinical characteristics. CKD was present in 26.1% of MF patients and was significantly associated with older age (P < 0.001), higher WBC (P = 0.015), and its subsets (neutrophil, monocyte, and basophil counts), higher platelets (P = 0.001), lower albumin (P = 0.018), higher serum uric acid (P = 0.001), higher LDH (P = 0.022), and the presence of CV risk factors (P = 0.011). There was no significant association with driver mutations, degree of bone marrow fibrosis, PMF/SMF, or DIPSS risk categories (P > 0.05 for all analyses). The presence of CKD was significantly associated with shorter time to arterial (HR = 3.49; P = 0.041) and venous thrombosis (HR = 7.08; P = 0.030) as well as with shorter overall survival (HR 2.08; P = 0.009). In multivariate analyses, CKD (HR = 1.8; P = 0.014) was associated with shorter survival independently of the DIPSS (HR = 2.7; P < 0.001); its effect being more pronounced in lower (HR = 3.56; P = 0.036) than higher DIPSS categories (HR = 2.07; P = 0.023). MF patients with CKD should be candidates for active management aimed at the improvement of renal function. Prospective studies defining the optimal therapeutic approach are highly needed.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleAnnals of Hematology
Numberingvol. 99, no. 12, pp. 2779-2785
p-ISSN0939-5555
e-ISSN1432-0584
DOIhttps://doi.org/10.1007/s00277-020-04239-4
URN:NBNurn:nbn:hr:105:588865
Publication2020-12
Document URLhttp://link.springer.com/10.1007/s00277-020-04239-4
Type of resourceText
Access conditionsOpen access
Embargo expiration date: 2022-01-01
Terms of useLicence In copyright icon
Created on2021-05-18 09:36:17